Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome.

Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane CG.

Pediatrics. 2002 Jun;109(6):1081-7.

PMID:
12042546
2.

Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome.

Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG.

Am J Respir Crit Care Med. 1999 Oct;160(4):1188-95.

PMID:
10508806
3.

Surfactant lavage treatment in a model of respiratory distress syndrome.

Cochrane CG, Revak SD.

Chest. 1999 Jul;116(1 Suppl):85S-86S. No abstract available.

PMID:
10424605
4.

Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome.

Cochrane CG, Revak SD, Merritt TA, Schraufstätter IU, Hoch RC, Henderson C, Andersson S, Takamori H, Oades ZG.

Pediatr Res. 1998 Nov;44(5):705-15.

PMID:
9803452
5.

Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys.

Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW, Kheiter A.

Pediatr Res. 1996 Apr;39(4 Pt 1):715-24.

PMID:
8848350
6.

The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome.

Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS.

Am J Respir Crit Care Med. 1996 Jan;153(1):404-10.

PMID:
8542150
7.

Protein-phospholipid interactions in pulmonary surfactant. The Parker B. Francis Lectureship.

Cochrane CG, Revak SD.

Chest. 1994 Mar;105(3 Suppl):57S-62S. Review.

PMID:
8131614
8.

Interactions of model human pulmonary surfactants with a mixed phospholipid bilayer assembly: Raman spectroscopic studies.

Vincent JS, Revak SD, Cochrane CD, Levin IW.

Biochemistry. 1993 Aug 17;32(32):8228-38.

PMID:
8347622
9.

Pulmonary surfactant protein B (SP-B): structure-function relationships.

Cochrane CG, Revak SD.

Science. 1991 Oct 25;254(5031):566-8.

PMID:
1948032
10.
11.

The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants.

Revak SD, Merritt TA, Hallman M, Heldt G, La Polla RJ, Hoey K, Houghten RA, Cochrane CG.

Pediatr Res. 1991 May;29(5):460-5.

PMID:
1896249
12.

Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity.

Revak SD, Merritt TA, Degryse E, Stefani L, Courtney M, Hallman M, Cochrane CG.

J Clin Invest. 1988 Mar;81(3):826-33.

13.

Biochemical events associated with pulmonary failure in shock and trauma.

Schraufstätter IU, Hyslop PA, Jackson J, Revak SD, Cochrane CG.

J Burn Care Rehabil. 1987 Nov-Dec;8(6):536-42.

PMID:
2449444
14.

Oxidant and protease injury of the lung.

Schraufstatter IU, Hyslop PA, Jackson J, Revak SD, Cochrane CC.

Bull Eur Physiopathol Respir. 1987 Jul-Aug;23(4):297-302.

PMID:
3690017
15.

Reconstitution of surfactant activity using purified human apoprotein and phospholipids measured in vitro and in vivo.

Revak SD, Merritt TA, Hallman M, Cochrane CG.

Am Rev Respir Dis. 1986 Dec;134(6):1258-65.

PMID:
3789526
16.

Human surfactant treatment of severe respiratory distress syndrome: pulmonary effluent indicators of lung inflammation.

Merritt TA, Hallman M, Holcomb K, Strayer D, Bloom B, Revak S, Cochrane CG.

J Pediatr. 1986 May;108(5 Pt 1):741-8.

PMID:
3486264
17.

Experimental pulmonary inflammatory injury in the monkey.

Revak SD, Rice CL, Schraufstätter IU, Halsey WA Jr, Bohl BP, Clancy RM, Cochrane CG.

J Clin Invest. 1985 Sep;76(3):1182-92.

18.

Biochemical factors in pulmonary inflammatory disease.

Schraufstatter I, Revak SD, Cochrane CG.

Fed Proc. 1984 Oct;43(13):2807-10.

PMID:
6383873
19.

Proteases and oxidants in experimental pulmonary inflammatory injury.

Schraufstätter IU, Revak SD, Cochrane CG.

J Clin Invest. 1984 Apr;73(4):1175-84.

20.

Anaphylactic release of a prekallikrein activator from human lung in vitro.

Meier HL, Kaplan AP, Lichtenstein LM, Revak S, Cochrane CG, Newball HH.

J Clin Invest. 1983 Aug;72(2):574-81.

21.

The plasma contact system in atopic asthma.

Lasser EC, Lang JH, Curd JG, Cochrane CG, Lyon SG, Howard MM, Hamblin AE, Revak SD.

J Allergy Clin Immunol. 1983 Jul;72(1):83-8.

PMID:
6189880
22.

Biochemical factors in pulmonary inflammatory disease.

Cochrane CG, Spragg RG, Revak SD, Schraufstatter I.

Chest. 1983 May;83(5 Suppl):67S-70S. No abstract available.

PMID:
6340987
23.
24.

The presence of neutrophil elastase and evidence of oxidation activity in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome.

Cochrane CG, Spragg RG, Revak SD, Cohen AB, McGuire WW.

Am Rev Respir Dis. 1983 Feb;127(2):S25-7. No abstract available.

PMID:
6550478
25.

Activation of Hageman factor by proteases released during antigen challenge of human lung.

Newball HH, Meier HL, Kaplan AP, Revak SD, Cochrane CG, Lichtenstein LM.

Trans Assoc Am Physicians. 1981;94:126-33. No abstract available.

PMID:
7046190
26.

Dissemination of contact activation in plasma by plasma kallikrein.

Cochrane CG, Revak SD.

J Exp Med. 1980 Sep 1;152(3):608-19.

27.

The participation of high molecular weight kininogen in hypotensive shock and intravascular coagulation.

Cochrane CG, Revak SD.

Clin Immunol Immunopathol. 1980 Mar;15(3):367-74. No abstract available.

PMID:
6154553
28.

Activation of human Hageman factor by a leukocytic protease.

Newball HH, Revak SD, Cochrane CG, Griffin JH, Lichtenstein LM.

Adv Exp Med Biol. 1979;120B:139-51.

PMID:
517231
29.
31.

Hageman factor: its structure and modes of activation.

Revak SD, Cochrane CG.

Thromb Haemost. 1976 Jun 30;35(3):570-5. No abstract available.

PMID:
989964
33.

Structural changes accompanying enzymatic activation of human Hageman factor.

Revak SD, Cochrane CG, Johnston AR, Hugli TE.

J Clin Invest. 1974 Sep;54(3):619-27.

34.

Soluble mediators of injury of the microvasculature; Hageman factor and the kinin forming, intrinsic clotting and the fibrinolytic systems.

Cochrane CG, Revak SD, Wuepper KD, Johnston A, Morrison DC, Ulevitch R.

Microvasc Res. 1974 Jul;8(1):112-21. No abstract available.

PMID:
4278273
35.

The relationship between PF-DIL and activated human Hageman factor.

Johnston AR, Cochrane CG, Revak SD.

J Immunol. 1974 Jul;113(1):103-9. No abstract available.

PMID:
4208914
36.

Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

Cochrane CG, Revak SD, Wuepper KD.

J Exp Med. 1973 Dec 1;138(6):1564-83.

37.

The interaction of Hageman factor and immune complexes.

Cochrane CG, Wuepper KD, Aiken BS, Revak SD, Spiegelberg HL.

J Clin Invest. 1972 Oct;51(10):2736-45.

Supplemental Content

Support Center